{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-021083","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.887619+00:00","generated_at":"2026-06-01T02:35:24.978743+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Contineum Therapeutics appoints Sarah Boyce to Board, effective June 24, 2024","bullets":["Sarah Boyce appointed as Class I director and Chair of Nominating and Corporate Governance Committee.","Boyce currently President & CEO of Avidity Biosciences (RNA); past roles include Akcea, Ionis, Forest Labs.","As non-employee director, receives standard compensation including initial option for 29,500 Class A shares.","Replaces Lori Lyons-Williams as Committee Chair; Lyons-Williams remains a member of the committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-021083","json":"https://secwatch.observer/filing/0001437749-24-021083.json","markdown":"https://secwatch.observer/filing/0001437749-24-021083.md","text":"https://secwatch.observer/filing/0001437749-24-021083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924021083/0001437749-24-021083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924021083/cont20240611_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:35:24.978743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efc8c09d62","claim":"Sarah Boyce was appointed as Class I Director and Chair of Nominating and Corporate Governance Committee at Contineum Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Sarah Boyce as a member of its Board, effective June 24, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924021083/0001437749-24-021083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director and Chair of Nominating and Corporate Governance Committee"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}